Four new compounds (N2, N3, N4) designed using QSARKPLS, QSARANN, and QSARSVR models show pIC50 activities comparable to Lead Li 39. They could be potential AChE inhibitors in AD treatment. This evidence concerns the gene ACHE and Alzheimer disease.